Silver Spike Acquisition Corp II
Silver Spike Acquisition Corp II — SPAC Merger (January 2022)
39 slides from Silver Spike Acquisition Corp II's SPAC merger presentation, Jan 20, 2022

Slide 1: Transaction Summary
Transaction Summary 1 Transaction StructureSilver Spike Acquisition Corp II (NASDAQ: SPKB) is a publicly listed special purpose acquisition company with $287.5million in cash in trustUpon completion of the transaction, former shareholders of Silver Spike and former shareholders of Eleusis will hold

Slide 2: Attractive Valuation Relative to Peers – Phase I Results May Drive Convergence
Attractive Valuation Relative to Peers – Phase I Results May Drive Convergence 2 Lead Candidate ELE-Psilo (Psilocin) COMP360 (Psilocybin) GH001 (5-MeO-DMT) Formulation IV Oral Intranasal Indication Major Depressive Disorder Treatment-Resistant Depression Treatment-Resistant Depression Clinical Stage

Slide 3: Transaction Details
Transaction Details Transaction summary Sources Cash in trust $288 Total uses $288 Uses Cash to balance sheet $258 Estimated transaction fees and expenses $30 Total uses $288 Illustrative share price $10.00 Pro forma shares outstanding (M) a 70.9 Total equity value $709 Net cash on balance sheet ($2

Slide 4: Eleusis at-a-glance
GD cleusis Eleusis at-a-glance Dedicated to transforming psychedelics into medicines for WE ARE DEVELOPING = A 2"4 generation investigational psilocybin-based drug ; sc candidate for Major Depressive Disorder (MDD) and a ZS I discovery platform for exploration beyond psychiatry : = Acare delivery ma

Slide 5: Key Investment Highlights
] Key Investment Highlights Significant Market Opportunity 2"4 Generation Psilocybin Drug Candidate for MDD A First-in-Class Care Delivery Management Company Antidepressant total addressable market (TAM) expected to reach $21bn by 2025+ US psychedelic care delivery TAM estimated to be ~$7bn2 ELE-Psi

Slide 6: Potential to Achieve Full Proof of Concept: ELE-Psilo Phase I Data by 2H 2022
| Potential to Achieve Full Proof of Concept: ELE-Psilo Phase | Data by 2H 2022, Care Delivery by 1H 2023 2021 2022 Clinical Development Program IND enabling Phase Ib Innovation Passport Designation granted as a part ° of MHRA’s Innovative Plan to Initiate Ph la Plan to Initiate Ph Ib ELE-Psi | (eo)

Slide 7: Leadership Team
| Leadership Team Deep Expertise Spanning Discovery, Development, and Delivery; 992 Peer-Reviewed Publications* ROB CONLEY SVP, Clinical Development SHLOMI RAZ Chief Executive Officer a KATHY KALUHIOKALANI President, Andala Qoprum UPMC DAVID WEINER, MD VP, Drug Discovery SS GENE RAMIREZ Chief Financ

Slide 8: Psychedelics May Transform the Treatment of Depression
GB cieusis Psychedelics May Transform the Treatment of Depression We aim to mainstream the transformation |. ELE-Psilo and Drug Discovery ll. Care Delivery Ill. Transaction Summary

Slide 9: Major Depressive Disorder (MDD) is the Silent Epidemic of the 21st Century
Adults in the US with depression symptoms prior to the pandemic? Major Depressive = — " Driving massive direct health care Disorder (MDD) expenditures? is the Silent Epidemic of the 21st Century $21 B+ ntidepressant total addressable market expected by 20253 S7 B Estimated psychedelic care delivery

Slide 10: Rapid, Robust, and Durable Antidepressant Effects of Psychedelics
] Rapid, Robust, and Durable Antidepressant Effects of Psychedelics Academic Preclinical and Clinical Study Observations Serotonergic psychedelics 5-HT ,, a ad Modulated Rapid, robust, Potential to 6 © onthe pathways and durable open a “critical associated with antidepressant window” for Downstream

Slide 11: Third Party Oral Psilocybin Proof of Concept Studies in MDD and Treatment Resistant Depression (TRD)
| Third Party Oral Psilocybin Proof of Concept Studies in MDD and Treatment Resistant Depression (TRD) Rapid, robust, and durable efficacy observed — but significant room for improvement MDD Clinical Study: Psilocybin (25mg) vs. Escitalopram? TRD Phase Ilb Study: Psilocybin (25mg, 10mg, 1mg)* No sta

Slide 12: Practical Limitations of Oral Psilocybin
| Practical Limitations of Oral Psilocybin Encapsulating psilocybin is only “half-way” to developing a useful drug therapy Single and Escalating Dose PK? Absorption rates varied between 40% to 70% in these academic studies 125 = a > E = 6 ; A r Subject 3 8B 71 g 8g 33 = se 8 cP 3 8 85 8 jf a 5 ag Ba

Slide 13: ELE-Psilo: A Potential Advance in Formulation
GD cleusis ELE-Psilo: A Potential Advance in Formulation Active moiety of psilocybin Designed for delivery via proprietary salt formulated for IV/infusion PSILOCIN CONSISTENT Formulated to reduce variability in drug exposure CONTROLLABLE Designed to be personalized and enable control over duration a

Slide 14: ELE-Psilo Target Profile
GD cieusis ELE-Psilo Target Profile Proposed om Rapid Acting Treatment of MDD Indication P 8 Proposed Proprietary Psilocin Salt Form in Formulation Ready-to-Use Vial Proposed Administration IV Infusion Potential Duration 10-to-30 min infusion of Administration <2 hours in-clinic Investigational Dose

Slide 15: IV Psilocybin Pharmacokinetics and Pharmacodynamics (PK/PD): Academic Studies
| IV Psilocybin Pharmacokinetics and Pharmacodynamics (PK/PD): Academic Studies IV administration enabled (1) immediate target drug intensity, and (2) greatly reduced treatment time and variability compared to oral administration Psilocin PK following IV and Oral Psilocybin IV Psilocybin PD QB ereus

Slide 16: Psilocin Receptor Occupancy, Drug Intensity, and Treatment Effect: Academic Studies
] Psilocin Receptor Occupancy, Drug Intensity, and Treatment Effect: Academic Studies Psilocin concentration 5-HT,, receptor occupancy was correlated with serotonin was correlated with 5-HT,, receptor occupancy? volunteer-reported drug intensity! 10.0- 100- Patient-reported is - 754 psychedelic drug

Slide 17: ELE-Psilo PK/PD Simulations
J ELE-Psilo PK/PD Simulations IV administration could rapidly reach target intensity and rapidly return below perceptual threshold Psilocin Concentration-Time Profile (Simulated) (10 and 20-minute IV Psilocin vs Oral 25 mg of Psilocybin) 100 = 3 5 Eleusis simulations suggest 5 J - target concentrati

Slide 18: ELE-Psilo - Potentially Favorable Differentiation
| ELE-Psilo - Potentially Favorable Differentiation | Psilocin Faller /2ite SASS) Formulation IV Oral Intranasal Onset / PK Design Attribute Designed to be Immediate with Low Observed to be Delayed and Highly Variable Observed to be Immediate and Highly Variability in Clinical Studies Variable Poten

Slide 19: ELE-Psilo IP Portfolio
J ELE-Psilo IP Portfolio Psilocin Salt Forms and Methods of Treatment Claimed Subject Matter Estimated Expiration? Composition of pharmaceutically acceptable salts of psilocin with improved stability, physical properties, 2041 and handling characteristics Pharmaceutically Acceptable Salts of Psiloci

Slide 20: Exploring Psychedelics Beyond Psychiatry - Eleusis Drug Discovery Platform
| Exploring Psychedelics Beyond Psychiatry - Eleusis Drug Discovery Platform Translation Mission Discovery Mission Identify new indications beyond psychiatry Advance a topically delivered therapy and expand new chemistry library for ocular disease Ubiquitous Expression Validated Target in Clarifying

Slide 21: Exploring Psychedelics Beyond Psychiatry - Eleusis Drug Discovery Platform
| Exploring Psychedelics Beyond Psychiatry - Eleusis Drug Discovery Platform Discovery Mission Translation Mission Identify new indications beyond psychiatry Advance a topically delivered therapy and expand new chemistry library for ocular disease Peer Allergic Conjunctivitis Posterior Uveitis? Tran

Slide 22: Psychedelic Drug Therapy Will Require Care Delivery Innovation
andala Psychedelic Drug Therapy Will Require Care Delivery Innovation Enabling Access to Insurance Covered Psychedelic Drug Treatment |. ELE-Psilo and Drug Discovery ll. Care Delivery lll. Transaction Summary

Slide 23: Addressing the "Last Mile" Challenge for Psychedelic Drug Therapy
i) andala OPPORTUNITY Addressing the “Last Mile” Challenge for Psychedelic Drug Therapy = Conventional psychiatric practice appears incompatible with psychedelic drug therapy = SPRAVATO roll-out highlights “last mile” challenge of specialty pharma in psychiatry = Requirement for supervised care deli

Slide 24: Establish Best-in-Class Platform for In-Network Care Delivery
(i) orarelel(e| MISSION Establish Best-in-Class Platform for In-Network Care Delivery = Provide patients seamless access to care = Secure in-network preferred provider status nationwide for Andala-managed clinics = Develop diversified referral pathways to increase access to care

Slide 25: Introducing Andala-Managed Clinics
| Introducing Andala-Managed Clinics* Address the “last mile” challenge of psychedelic drug therapy Opportunity $7bnt TAM (US) Iestnct cosumes 0A approved psyehedec drug andala therapy for MDD, PTSD, and substance abuse) : . 15 Anticipated 2" Anticipated Business In-network high-throughput f P . P :

Slide 26: Andala-Managed Clinic Prototype - Estimated Unit Level Economics
Cee tg Patient Population ~5.7m large group covered lives in prototype region? ~60k TRD patients covered? ~1% TRD patient acquisition required for full capacitation? FA Clinic Capacitation Capacity for 9,000 treatments per year per clinic* Clinics aim to: v Treat 30 new patients per month within 4 m

Slide 27: Care Delivery Model Comparison
j Care Delivery Model Comparison Reimbursement Model PWETEL)( Therapies Patient Acquis’ (Referral Sources) Oversight and Safety Monitoring Andala-Managed Clinics Expected coverage and reimbursement by large insurance providers SPRAVATO (generally covered) IV/IM Ketamine if ineligible for SPRAVATO (p

Slide 28: Transaction Summary
& eleusis Transaction Summary |. ELE-Psilo and Drug Discovery Il. Care Delivery Ill. Transaction Summary

Slide 29: Transaction Summary
| Transaction Summary Transaction Structure Silver Spike Acquisition Corp II (NASDAQ; SPKB) is a publicly listed special purpose acquisition company with $287.5 million in cash in trust Upon completion of the transaction, former shareholders of Silver Spike and former shareholders of Eleusis will ho

Slide 30: Attractive Valuation Relative to Peers — Phase I Results May Drive Convergence
| Attractive Valuation Relative to Peers — Phase | Results May Drive Convergence Lead Candidate Formulation Indication Clinical Stage Drug Discovery Platform Care Delivery Services Enterprise Value (USD) eleusis ELE-Psilo (Psilocin) IV Major Depressive Disorder Anticipated Phase | Results in 2H 2022

Slide 31: Eleusis is Ready to Transform Psychedelics into Medicines for Living
] Eleusis is Ready to Transform Psychedelics into Medicines for Living Significant Market Opportunity Antidepressant TAM ~S21bn!1 + Psychedelic Care Delivery TAM ~$7bn? ELE-Psilo — Transforming psilocybin into modern drug therapy for MDD Anticipated initiation of Phase | study in 1H 2022 Anticipated

Slide 32: EB) eleusis
EB) eleusis

Slide 33: Appendix
EB cieusis Appendix

Slide 34: Transaction Details
] Transaction Details Transaction summary Pro forma enterprise value of $446 million with 100% rollover by existing Eleusis equityholders™ Eleusis equityholders to receive additional earnout shares at closing equal to approximately 14% of an adjusted measure of pro forma enterprise value, vesting: *

Slide 35: Use of Proceeds
| Use of Proceeds SPKB trust account together with existing cash and cash equivalents will be used to support the following: Clinical development of ELE-Psilo in MDD into Ph2/3 trials Launch and expansion of Andala-managed clinics Drug discovery platform expansion Clinical development of ELE-Psilo i

Slide 36: Board of Directors and Psychiatric Advisory Board
| Board of Directors and Psychiatric Advisory Board PSYCHIATRIC ADVISORY BOARD EXPECTED POST-MERGER INDEPENDENT DIREC GEORGE PAPAKOSTAS HARVARD Ear @ capence Phathom Chairman PHARMACEUTICALS PHARMACEUTICALS SAMUEL WILKINSON Yale sCHOOL OF MEDICINE Former Director of FDA Division TOM LAUGHREN @ SCOTT

Slide 37: Significant 5-HT2A Focused Expertise Drives Drug Discovery Platform
] Significant 5-HT,, Focused Expertise Drives Drug Discovery Platform 626 Publications and 180 Years of Experience? Mechanism of Action Charles Nichols, PhD Professor of Pharmacology Scientific Founder & Sponsored Researcher LSU Health Focus: MOA, SAR, translational disease models Timothy Foster, Ph

Slide 38: Highly Experienced Silver Spike Capital Team
| Highly Experienced Silver Spike Capital Team Senior Management Scott Gordon, Founder, CEO and Chairman + Scott was co-Founder & Chairman of Egg Rock Holdings, the parent company of Papa & Barkley — a leading California based cannabis company + Scott has over 30 years of emerging markets and distre

Slide 39: Applicable Recent deSPAC Experience — SSPK merger with WM Holdings
] Applicable Recent deSPAC Experience — SSPK merger with WM Holdings Silver Spike successfully listed a $250M Special Purpose Acquisition Company (SPAC) on the Nasdaq (ticker: SSPK) in August 2019, representing the first Cannabis SPAC underwritten by a global investment bank in the US, Credit Suisse
Source: SEC EDGAR · 8-K filed Jan 20, 2022